A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.

Trial Details

NCT ID
NCT07099430
Phase
PHASE1 / PHASE2
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • LBL-024 for Injection
  • Toripalimab Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily en…
  • At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.
  • The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
  • The expected survival time is at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →